You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
NEWS / EVENTS / .........

EVENTS - 30-10-2008

New method for the purification of Factor VIII VIII/FVW concentrate study published on

 The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307,

Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated for industrial feasibility.

The authors of the study are Filippo Mori, Ilaria Nardini, Paola Rossi, Claudio Farina (basic research manager) and Claudia Nardini (industrial research and development manager).

The trial described in the article helped develop a new purification process for Factor VIII/von Willebrand factor with a high yield and purity. Once the chromatographic parameters are optimised, the selected resin (Fractogel EMD TMAE) can process twice as much product as the ordinary production process, which will also save on processing time. The new purification process can be used to adjust the vWF content in the end product, so the result will be one or more very pure and stable drugs specifically designed to treat Haemophilia A or Von Willebrand disease

Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.

For more information please contact: pressoffice@kedrion.com